LON:OXB Oxford Biomedica (OXB) Share Forecast, Price & News GBX 469 +6.50 (+1.41%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range 458.50▼ 46950-Day Range 401▼ 46952-Week Range 276.62▼ 575Volume39,861 shsAverage Volume102,604 shsMarket Capitalization£454.74 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 1,010 ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines About Oxford Biomedica (LON:OXB) StockOxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.Read More Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address OXB Stock News HeadlinesMay 26, 2023 | americanbankingnews.comOxford Biomedica (LON:OXB) Price Target Cut to GBX 1,010May 25, 2023 | msn.comRBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform RecommendationJune 6, 2023 | UNKNOWN (Ad)The Stock That's Brining Lithium Back To America!The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S SoilMay 15, 2023 | finance.yahoo.comOxford Biomedica launches TetraVecta - the next generation lentiviral vector systemMay 5, 2023 | finance.yahoo.comWhy Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/SApril 26, 2023 | finance.yahoo.comOxford Biomedica Appoints Leone Patterson as Non-Executive DirectorApril 25, 2023 | markets.businessinsider.comOxford Biomedica Posts FY LossApril 21, 2023 | marketwatch.com2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and ForecastJune 6, 2023 | UNKNOWN (Ad)Lithium Has Boomed And This American Stock Is Ready..Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!April 12, 2023 | marketwatch.com2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern TrendMarch 26, 2023 | marketwatch.comCGT CDMO Market Share and Forecast till 2030March 15, 2023 | benzinga.comOxford BioMedica Stock (OTC:OXBDF), Quotes and News SummaryMarch 11, 2023 | finance.yahoo.comAs Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this yearFebruary 25, 2023 | marketwatch.comWhat is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key PlayersFebruary 22, 2023 | marketwatch.comCGT CDMO Market Size Global Research Report, 2023 - 2028January 30, 2023 | marketwatch.comCGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028January 20, 2023 | marketwatch.comCGT CDMO Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028January 12, 2023 | marketwatch.comCGT CDMO Market Present Development Scenario and Growth Prospects to help you understand the Implications for Your Business | Newest 112 InsightsJanuary 1, 2023 | finance.yahoo.comA Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)December 14, 2022 | yahoo.comOxford Biomedica Solutions forms new partnerships with three biotechnology companiesDecember 9, 2022 | marketwatch.comCGT CDMO Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028November 22, 2022 | finance.yahoo.comOxford Biomedica Appoints Dr Frank Mathias as Chief Executive OfficerOctober 25, 2022 | marketwatch.comCGT CDMO Market Size 2022 Is Changing Consumer Habits, this Industry in the Globe Has Noticed Substantial Growth to 2028 | 112 Pages ReportOctober 7, 2022 | finance.yahoo.comAmendment of Short-Term Loan Facility into new Term Loan Facility With OaktreeSeptember 29, 2022 | finance.yahoo.comBullish Oxford Biomedica plc (LON:OXB) insiders filled their treasuries with UK£658k worth of stock over last yearSeptember 15, 2022 | finance.yahoo.comEdited Transcript of OXB.L earnings conference call or presentation 15-Sep-22 12:00pm GMTSeptember 15, 2022 | uk.finance.yahoo.comFTSE: Oxford Biomedica sees revenue drop as COVID vaccine demand dropsSee More Headlines OXB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:OXB CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees744Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 1,010 High Stock Price ForecastGBX 1,010 Low Stock Price ForecastGBX 1,010 Forecasted Upside/Downside+115.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-39,160,000.00 Net Margins-27.97% Pretax MarginN/A Return on Equity-21.33% Return on Assets-8.33% Debt Debt-to-Equity Ratio48.38 Current Ratio3.61 Quick Ratio1.67 Sales & Book Value Annual Sales£139.99 million Price / Sales3.25 Cash FlowGBX 156 per share Price / Cash Flow3.01 Book ValueGBX 213 per share Price / Book2.20Miscellaneous Outstanding Shares96,960,000Free FloatN/AMarket Cap£454.74 million OptionableNot Optionable Beta0.92 Key ExecutivesDr. Roch DoliveuxInterim CEO & ChairmanMr. Stuart Paynter (Age 49)CFO, Company Sec. & Director Comp: $755kMr. Nick PageChief Operations OfficerDr. James Miskin Ph.D.Chief Technical OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Scientific OfficerMr. Matthew TreagusChief Information OfficerSophia BolhassanHead of Investor RelationsMs. Natalie Louise WalterGen. CounselDr. Jason Slingsby MBAChief Bus. & Corp. Devel. OfficerMs. Sarah MacleodHead of CommunicationsMore ExecutivesKey CompetitorsSilence TherapeuticsLON:SLNErgomedLON:ERGOHorizon Discovery Group plc (HZD.L)LON:HZDVerona Pharma plc (VRP.L)LON:VRPPureTech HealthLON:PRTCView All CompetitorsInsidersCatherine MoukheibirBought 8,910 shares on 10/11/2022Total: £2.82 M ($317.00/share)View All Insider Transactions OXB Stock - Frequently Asked Questions Should I buy or sell Oxford Biomedica stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OXB shares. View OXB analyst ratings or view top-rated stocks. What is Oxford Biomedica's stock price forecast for 2023? 1 equities research analysts have issued 12 month price objectives for Oxford Biomedica's shares. Their OXB share price forecasts range from GBX 1,010 to GBX 1,010. On average, they predict the company's stock price to reach GBX 1,010 in the next year. This suggests a possible upside of 115.4% from the stock's current price. View analysts price targets for OXB or view top-rated stocks among Wall Street analysts. How have OXB shares performed in 2023? Oxford Biomedica's stock was trading at GBX 442.50 on January 1st, 2023. Since then, OXB stock has increased by 6.0% and is now trading at GBX 469. View the best growth stocks for 2023 here. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL). What is Oxford Biomedica's stock symbol? Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB." How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Oxford Biomedica's stock price today? One share of OXB stock can currently be purchased for approximately GBX 469. How much money does Oxford Biomedica make? Oxford Biomedica (LON:OXB) has a market capitalization of £454.74 million and generates £139.99 million in revenue each year. The biopharmaceutical company earns £-39,160,000.00 in net income (profit) each year or GBX (0.42) on an earnings per share basis. How many employees does Oxford Biomedica have? The company employs 744 workers across the globe. How can I contact Oxford Biomedica? Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for the company is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000. This page (LON:OXB) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.